What is the appropriate management of a drug eruption?

Management of Drug Eruption

Immediately discontinue the suspected causative drug and provide supportive care, with the intensity of treatment escalating based on severity: mild eruptions require only drug withdrawal and symptomatic relief, while severe reactions (SJS/TEN, DRESS) demand immediate systemic corticosteroids (0.5-2 mg/kg/day) and potential ICU admission 1.

Initial Assessment and Risk Stratification

When evaluating a drug eruption, rapidly identify red flags that distinguish benign from life-threatening reactions:

Severe reaction warning signs:

• Mucosal erosions (oral, genital, ocular)
• Skin pain or tenderness
• Fever and systemic symptoms
• Bullous or exfoliative skin changes
• Facial edema or target lesions
• Eosinophilia with systemic involvement

These features suggest Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), DRESS syndrome, or acute generalized exanthematous pustulosis (AGEP), which carry significant mortality risk 2, 3.

Management Algorithm by Severity

Mild to Moderate Drug Eruptions (Morbilliform, Urticarial)

Primary intervention: Stop the offending medication immediately 2.

Symptomatic management:

• H1-antihistamines for pruritus
• Topical corticosteroids for localized inflammation
• Emollients for xerosis
• Monitor for progression over 24-48 hours

Most mild eruptions resolve within days to weeks after drug discontinuation 4. The key pitfall here is continuing the medication "to see if it gets better"—it won't, and you risk progression to severe disease 5.

Moderate Eruptions with Specific Features

For EGFR-TKI-related acneiform eruptions (common with cancer therapy):

• Topical corticosteroids to seborrheic areas (face, scalp, chest, upper back)
• Oral antibiotics (doxycycline or minocycline) for superinfected lesions
• Consider dose reduction rather than complete discontinuation if tumor response is favorable
• Prophylactic doxycycline or minocycline may prevent rash development 1

For fixed drug eruption:

• Drug avoidance is definitive treatment
• Antihistamines for pruritus
• Expect post-inflammatory hyperpigmentation that persists for months 4
• Lesions recur in identical locations with re-exposure, making identification critical

Severe Cutaneous Adverse Reactions (SCAR)

For SJS/TEN, DRESS, or AGEP:

Immediate actions:

• Stop ALL potentially causative medications immediately—do not wait for confirmation 6
• Transfer to ICU or burn unit for extensive skin detachment (>10% body surface area)
• Initiate systemic corticosteroids: 0.5-2 mg/kg/day prednisone equivalent, tapered over 4-6 weeks 1
• Provide supportive care: fluid/electrolyte management, wound care, nutritional support, infection surveillance

Critical caveat: For bullous or exfoliative rashes, immediate drug discontinuation is non-negotiable—any delay increases mortality 1. The mortality rate for SJS/TEN can reach 30-40% without prompt intervention 3.

For steroid-refractory cases:

• Consider disease-specific immunomodulators
• IVIG or cyclosporine may be options for SJS/TEN (though evidence is mixed)
• Multidisciplinary consultation (dermatology, critical care, ophthalmology for ocular involvement)

Special Consideration: Immune Checkpoint Inhibitors (ICI)

For ICI-related cutaneous toxicity with systemic involvement:

• Grade 1-2: Continue ICI with topical corticosteroids
• Grade 3-4: Hold ICI, initiate systemic corticosteroids (0.5-2 mg/kg/day tapered over 4-6 weeks) 1
• Rechallenge decision requires shared decision-making weighing tumor response against recurrence risk (which is <50% but higher for colitis, pneumonitis, hepatitis) 1
• Grade 4 reactions are typically considered absolute contraindications to rechallenge

Diagnostic Confirmation

While management should never be delayed for testing, subsequent identification of the culprit drug prevents future reactions:

• Drug-induced lymphocyte stimulation test
• Patch testing (for fixed drug eruption, delayed reactions)
• Drug provocation testing (only for non-severe reactions, never for SJS/TEN/DRESS)

Select testing modality based on clinical phenotype and severity 7. The goal is preventing inappropriate drug allergy labeling while ensuring patient safety.

Common Pitfalls to Avoid

• Continuing the drug "just one more dose" while monitoring—this can precipitate rapid progression to severe disease
• Assuming viral exanthem without considering drug timing—drug eruptions typically occur 7-14 days after drug initiation (or 24 hours for fixed drug eruption with prior exposure) 8
• Failing to examine mucous membranes—mucosal involvement is the hallmark distinguishing severe from benign reactions 6
• Inadequate corticosteroid duration—tapering too quickly (less than 4 weeks) in DRESS can cause rebound flares 1